Chugai skyrockets on Roche buyout rumors; Apotex recalls transplant drug;

@FiercePharma: Top-read on FP this weekend: Bloomberg: Roche negotiating for rest of Chugai for $10B. Report | Follow @FiercePharma

@TracyStaton: Been on vacay? FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. Story | Follow @TracyStaton

@EricPFierce: ICYMI last week: Zytiga fight heats up between J&J, NICE, stirred by anxious cancer patients. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: FDA sets decision date for Pfizer's MenB candidate. More | Follow @CarlyHFierce

> Japan's Chugai Pharmaceutical saw its shares soar Monday on media reports that top shareholder Roche ($RHHBY) plans to buy the 40% share of the company it doesn't already own; Chugai denies any such talks. Report

> Canada's generics maker Apotex pulled one lot of its organ rejection drug Apo-Mycophenolic Acid because of a labeling error, Health Canada said. Report

> The Brazilian generics maker EMS Participacoes flooded pharmacies with its version of the Pfizer ($PFE) erectile dysfunction drug Viagra as the blockbuster drug's patent expired in that country. Report

> Abbott Laboratories ($ABT) and its spun-off pharma subsidiary AbbVie ($ABBV) won final dismissal of a payer lawsuit claiming damages for alleged off-label marketing of the seizure drug Depakote. Report

> Two brothers convicted of insider trading for buying shares of Chattem ahead of its buyout by Sanofi ($SNY) can't skirt their conviction, a judge ruled. Report

Medical Device News

@FierceMedDev: ICYMI: FDA approves ear inserts to reduce TMJ pain. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients. Story | Follow @StacyALawrence

@VarunSaxena2: RT @FierceMedDev: We're looking for fierce women at the top of their game in med tech. Learn more about how to nominate. | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Top U.S. senator urges Hospira to abandon inversion plans. Article | Follow @EmilyWFierce

> China's top health authority calls for more homegrown med tech. More

> Abbott gets $20M from DOD to develop portable concussion test. Story

> After Walgreens avoids inversion, will Medtronic modify its Covidien offer? Item

Biotech News

@FierceBiotech: After a few days in Copenhagen, looks like Novo's fine today amounts to dinner for 6, with wine. Report | Follow @FierceBiotech

@JohnCFierce: Norway, Denmark and now Sweden. Too bad I won't make Finland. Should be interesting to see how Stockholm has changed in the last 10 years. | Follow @JohnCFierce

@DamianFierce: $NVO's CEO on the house that Victoza built and the future of diabetes R&D. Story | Follow @DamianFierce

@EmilyMFierce: ICYMI: Chikungunya vaccine shows antibody response in Phase I trial. Story | Follow @EmilyMFierce

> Novartis circles back with new terms for a stem cell biotech buyout--report. More

> Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU. News

> Novo Nordisk accepts a $90K slap on the hand for delaying news of Tresiba setback. Report

> Are they or aren't they? Chugai spurns reports of Roche takeover talks. Article

CRO News

> Shire bails out a contractor to keep its drug on the market. Report

> Evotec rides its risk-sharing model to revenue growth. Article

> AMRI swings to revenue growth amid a transitional year. News

> ABL teams up with Expression Therapeutics on a hemophilia treatment. Item

> Almac pours $90M into N. Ireland, adding 350 jobs. Story

Biotech IT News

> Validic raises $5M to fuel 'crazy' growth of data aggregation platform. News

> Top U.S. universities join project to apply Big Data to social problems. Item

> Oxford Nanopore raises $59M to scale up production of MinION sequencer. More

> Survey: Scientists talk on Twitter, network on ResearchGate. Story

> Pfizer continues to explore virtual trials with 23andMe pact. Article

Animal Health News

> Kindred Biosciences' loss grows in the face of development costs. Story

> Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis. Item

> Sales of pet products take a dive at Central Garden & Pet. More

> Australia's Jurox launches anesthetic in U.S. two months after setting up American operations. Article

> Elanco closing former ChemGen plant, moving production to the U.K. More

And Finally... Circadian rhythm disruptions like jet lag can have profound health consequences. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.